Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor

NCT00793871 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

Interventions

DRUG: Sunitinib Malate (SU011248)

Sponsor

Pfizer